NCT03399734 is a Phase 1 clinical trial of Perampanel in Healthy Participants, sponsored by Eisai Co., Ltd..

Who is sponsoring NCT03399734?

NCT03399734 is sponsored by Eisai Co., Ltd..

What drugs are being tested in NCT03399734?

Interventions in NCT03399734: Perampanel, Perampanel.

What condition does NCT03399734 study?

NCT03399734 studies Healthy Participants.

Is NCT03399734 still recruiting?

NCT03399734 is currently completed. Last updated 29 October 2018.

Last reviewed 2018-10-29 · How we verify

NCT03399734

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Completed Phase 1 Last updated 29 October 2018

What this trial tests

Phase 1 trial testing Perampanel in Healthy Participants in 24 participants. Completed in 9 March 2018.

Timeline

18 December 2017

Primary endpoint
9 March 2018

9 March 2018

Quick facts

Lead sponsor	Eisai Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	24
Start date	18 December 2017
Primary completion	9 March 2018
Estimated completion	9 March 2018
Sites	1 location across Japan

Drugs / interventions tested

Perampanel (PERAMPANEL) — full drug profile →
Perampanel (PERAMPANEL) — full drug profile →

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

Adults 20 to 45, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be conducted to demonstrate the bioequivalence between a single 4 milligram (mg) dose of fine granules of perampanel and a single 4 mg tablet of perampanel.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects.
Shiba S, Sekino H, Ishiba K, Yasuda S, et al · · 2020 · cited 4× · PMID 32870153 · DOI 10.5414/cp203781

Verify or expand the search:

Other trials of Perampanel

Trials testing the same drug.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
NCT04309721 — Perampanel in Focal Status Epilepticus · Phase 3 · terminated
NCT05533814 — A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizure · Phase 4 · completed

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03399734 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 29 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03399734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing